colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate
COLY-MYCIN S (colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate) by Pfizer is clinical pharmacology colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Approved for superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics. First approved in 1962.
Drug data last refreshed 15h ago · AI intelligence enriched 6d ago
COLY-MYCIN S is a fixed-dose combination otic suspension containing colistin sulfate (polypeptide antibiotic), neomycin sulfate (aminoglycoside antibiotic), thonzonium bromide (surfactant), and hydrocortisone acetate (corticosteroid). It treats superficial bacterial infections of the external auditory canal caused by susceptible gram-positive and gram-negative organisms including Pseudomonas aeruginosa and Staphylococcus aureus. The combination works through dual bactericidal action via bacterial cell membrane disruption and protein synthesis inhibition, plus anti-inflammatory control of edema and pruritus.
Product is in late-stage lifecycle approaching loss of exclusivity with moderate competitive pressure (30%), indicating defensive positioning and potential resource consolidation within the brand team.
CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a…
Worked on COLY-MYCIN S at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on COLY-MYCIN S offers limited upside given approaching loss of exclusivity and zero linked job postings, making it a consolidation or support role rather than a growth platform. Career value lies in defensive strategy execution, generic mitigation, and operational efficiency rather than market expansion or innovation.